Lineage Cell Therapeutics, Inc. (LCTX) News
Filter LCTX News Items
LCTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
LCTX News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest LCTX News From Around the Web
Below are the latest news stories about LINEAGE CELL THERAPEUTICS INC that investors may wish to consider to help them evaluate LCTX as an investment opportunity.
Lineage Cell Therapeutics Issues Letter to StockholdersCARLSBAD, Calif., January 06, 2025--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today published a letter to shareholders highlighting the company’s recent achievements and outlook for 2025. |
Lineage Cell price target lowered to $2 from $3 at D. Boral CapitalD. Boral Capital lowered the firm’s price target on Lineage Cell Therapeutics (LCTX) to $2 from $3 and keeps a Buy rating on the shares. The firm adjusted the company’s model for the new shares. The analyst says Lineage enters 2025 with “strong” operational progress, bolstered by a recent capital raise that extends its cash runway to support ongoing clinical trials and development programs. Key catalysts in the year ahead include pivotal updates from the OpRegen program for dry age-related macul |
Down -43.14% in 4 Weeks, Here's Why Lineage Cell (LCTX) Looks Ripe for a TurnaroundThe heavy selling pressure might have exhausted for Lineage Cell (LCTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
Is Lineage (LINE) the Best New Pick in Brad Gerstner’s Portfolio?We recently published a list of 7 new stock picks in Brad Gerstner’s portfolio. In this article, we are going to take a look at where Lineage, Inc. (NASDAQ:LINE) stands against other stock picks in Brad Gerstner’s portfolio. Gerstner Expects More M&As in New Term Strategists and investors are confident that the new administration will […] |
Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct OfferingCARLSBAD, Calif., November 21, 2024--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the first closing of its previously announced registered direct offering for the purchase and sale of up to an aggregate of 39,473,688 of Lineage’s common shares and accompanying warrants (the "common warrants") to purchase an aggregate of up to 39,473,688 of Lineage’s common share |
Lineage Cell (LCTX) Loses -26.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerLineage Cell (LCTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct OfferingCARLSBAD, Calif., November 20, 2024--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it entered into definitive agreements with certain healthcare focused institutional investors and with Broadwood Partners, L.P. ("Broadwood"), an affiliate of Neal Bradsher, a member of Lineage’s board of directors, for the purchase and sale of up to an aggregate of 39,473,688 |
Lineage Cell Therapeutics Inc (LCTX) Q3 2024 Earnings Call Highlights: Strategic Advances and ...Lineage Cell Therapeutics Inc (LCTX) extends its cash runway and progresses in key partnerships, despite facing regulatory and financial hurdles. |
Lineage Cell (LCTX) Reports Q3 Loss, Tops Revenue EstimatesLineage Cell (LCTX) delivered earnings and revenue surprises of 50% and 222.99%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateCARLSBAD, Calif., November 14, 2024--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its third quarter 2024 financial and operating results. The Company will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and to provide a business update. |